Figure 8 (IMAGE)
Caption
MLN4924 treatment induces DNA damage by stabilizing CDT1 and accumulates the cells in S phase which are enhanced by MLN4924/cisplatin co-treatment. (A) Representative images of Ki-67 staining (40× magnification) and quantitation of Ki-67 IHC. The results were from 4 tumors and data were presented as mean ± SD. **p < 0.001 indicates a significant difference. (B) WB showing the levels of cleaved PARP, CDT1, γH2AX and p21 in vehicle, MLN4924, Cisplatin, and MLN4924/Cisplatin treated tumors. (C) A model showing the pathway leading to apoptosis and senescence upon NAE1 inhibition by MLN4924 and synthetic lethality upon MLN4924/cisplatin cotreatment.
Credit
Correspondence to - Alo Ray - Alo.Ray@osumc.edu
Usage Restrictions
CCBY
License
Licensed content